Review paper

Emerging therapeutic modalities of PARP inhibitors in breast cancer

Volume: 68, Pages: 62 - 68
Published: Jul 1, 2018
Abstract
Inhibition of Poly (ADP-ribose) polymerase (PARP) has shown marked benefit for breast cancer with homologous recombination deficiency, whether driven by defects in BRCA1, BRCA2, or other pathway components. Since the initial approval of olaparib, a mostly investigated PARP inhibitor (PARPi), the clinical development of PARPi in breast cancer treatment has been a major emphasis. Researches in investigating platinum-PARPi combination use compared...
Paper Details
Title
Emerging therapeutic modalities of PARP inhibitors in breast cancer
Published Date
Jul 1, 2018
Volume
68
Pages
62 - 68
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.